MPH MD - NRX Pharmaceuticals Chief CoFounder

NRXP Stock  USD 2.05  0.30  12.77%   

Insider

MPH MD is Chief CoFounder of NRX Pharmaceuticals
Age 68
Phone484 254 6134
Webhttps://www.nrxpharma.com

NRX Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (1.4566) % which means that it has lost $1.4566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8261) %, meaning that it created substantial loss on money invested by shareholders. NRX Pharmaceuticals' management efficiency ratios could be used to measure how well NRX Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
NRX Pharmaceuticals currently holds 9.16 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. NRX Pharmaceuticals has a current ratio of 4.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NRX Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Susan KahlertSenti Biosciences
N/A
Ronald CPARenovoRx
N/A
KwanHong MDLongeveron LLC
57
Amro AlbannaAditxt Inc
55
Assaf OronBiomx Inc
50
MD FACCLongeveron LLC
62
DDS MSAditxt Inc
59
Wilson WongSenti Biosciences
N/A
Rowena AlbannaAditxt Inc
59
Philip LeeSenti Biosciences
42
Cameron ShawVirax Biolabs Group
37
Merav BassanBiomx Inc
59
Inbal BenjaminiElranBiomx Inc
N/A
Vanessa CarleLexaria Bioscience Corp
N/A
Denise CarterQuoin Pharmaceuticals Ltd
56
CPA CMALexaria Bioscience Corp
63
James AhlersRenovoRx
60
Philip AinslieLexaria Bioscience Corp
N/A
Eran MDBiomx Inc
N/A
Jeffrey PharmDNutriband
55
James CPALongeveron LLC
58
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. NRX Pharmaceuticals (NRXP) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 14 people. NRX Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

NRX Pharmaceuticals Leadership Team

Elected by the shareholders, the NRX Pharmaceuticals' board of directors comprises two types of representatives: NRX Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NRX. The board's role is to monitor NRX Pharmaceuticals' management team and ensure that shareholders' interests are well served. NRX Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NRX Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Suzanne Messere, Investor Relations
Michael Abrams, Chief Officer
Robert MIM, Chief Operations
Michael Kunz, Gen Sec
Stephen Esq, CEO Secretary
Richard Narido, Principal CFO
Molly Cogan, Sr Affairs
Seth Voorhees, CFO Treasurer
Dennis McBride, Chief Scientist
Matthew Duffy, Chief Therapeutics
Prof Javitt, CoFounder Board
Riccardo Panicucci, Chief Officer
MPH MD, Chief CoFounder
Philip Lavin, Chief Methodologist

NRX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NRX Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.